Stay ahead, live with peace of mind
CancerTRACE™ liquid biopsy is designed specifically to help cancer survivors stay ahead and live with peace of mind. This non-invasive technology analyzes a patient’s blood to detect any changes in their cancer status, providing an early warning system for potential recurrence. By monitoring cancer recurrence at the earliest stages, CancerTRACE™ gives patients the opportunity to take control of their health and receive the necessary treatments in a timely manner.
Stay Ahead of Recurrence with Cell-Free DNA (cfDNA) Liquid Biopsy Monitoring.
Cell-free DNA (cfDNA) carries real-time information that can be used to detect and monitor biomarkers of cancer and other diseases in a simple blood test. cfDNA is often found in low concentrations with rare mutations or in a fragmented condition, and you need reliable tools that give you confidence in the signal you detect.
-
Detection of minimal (or molecular) residual disease (MRD) following surgical resection of the primary tumor and in guiding adjuvant therapy
-
Assessment of clinical response to neoadjuvant chemotherapy and/or radiotherapy
-
Monitoring of response to palliative drug therapies
-
Tracking of clonal dynamics and evolution during targeted therapy
-
The enrichment and selection of patients for clinical trials of novel anti-cancer therapies
Key Benefits of CancerTRACE™
Detects cancer DNA in the bloodstream before tumors are visible
CancerTRACE™ is designed to identify circulating tumor DNA in the bloodstream even before tumors are visible through conventional imaging. With its high sensitivity, the test can detect the smallest traces of recurrence, giving doctors and patients a critical head start in managing cancer effectively.
Tracks changes across multiple genes linked to cancer
Unlike traditional biopsies that can be invasive and risky, CancerTRACE™ requires only a simple blood draw. This makes it possible to monitor patients more frequently and in real time, providing doctors with ongoing insights into disease progression or remission. By tracking changes across multiple genes associated with cancer, it enables smarter and more precise monitoring strategies.
Applicable to a wide range of cancer types, including solid and blood cancers
CancerTRACE™ is applicable to a wide range of cancers, including both solid and blood-based tumors, making it a versatile choice for many patients. Because it is non-invasive and widely accessible, it can be performed at multiple locations and repeated as often as needed. At the same time, it is more affordable compared to surgical biopsies, reducing both financial and physical burdens for patients.
Transform Cancer Care with Precision Medicine
Our comprehensive genomic profiling tests provide information about clinically relevant biomarkers and genomic alterations to help match patients to approved targeted therapies, immunotherapies, and clinical trial options — giving physicians and patients powerful actionable insights for navigating cancer care.